| Title | Author(s) | Year | View Count |  | Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay | Seto, WK; Tanaka, Y; Wong, DKH; Lai, CL; Shinkai, N; Yuen, JCH; Tong, T; Fung, J; Hung, IFN; Yuen, MF | 2013 | 87 |
| Phosphorescent molecular tweezers based on alkynylplatinum(II) terpyridine system: turning on of NIR emission via heterologous Pt...M interactions (M = PtII, PdII, AuIII and AuI) | Tanaka, Y; Wong, KMC; Yam, VWW | 2012 | 169 |
 | Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay | Seto, WKW; Tanaka, Y; Wong, DKH; Lai, CL; Shinkai, N; Yuen, JCH; Tong, T; Fung, JYY; Hung, IFN; Yuen, RMF | 2012 | 5 |
 | No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. | Sawai, H; Nishida, N; Mbarek, H; Matsuda, K; Mawatari, Y; Yamaoka, M; Hige, S; Kang, JH; Abe, K; Mochida, S; Watanabe, M; Kurosaki, M; Asahina, Y; Izumi, N; Honda, M; Kaneko, S; Tanaka, E; Matsuura, K; Itoh, Y; Mita, E; Korenaga, M; Hno, K; Murawaki, Y; Hiasa, Y; Ide, T; Ito, K; Sugiyama, M; Ahn, SH; Han, KH; Park, JY; Yuen, RMF; Nakamura, Y; Tanaka, Y; Mizokami, M; Mizokami, M; Tokunaga, K | 2012 | 65 |
| The effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6 | Seto, WK; Tanaka, Y; Liu, K; Lai, CL; Yuen, MF | 2011 | 357 |
| Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection | Yuen, MF; Wong, DKH; Lee, CK; Tanaka, Y; Allain, JP; Fung, J; Leung, J; Lin, CK; Sugiyama, M; Sugauchi, F; Mizokami, M; Lai, CL | 2011 | 378 |
| Evidence of serologic activity in chronic hepatitis B after surface antigen (HBSAG) seroclearance | Seto, WK; Tanaka, Y; Wong, D; Lai, CL; Shinkai, N; Yuen, JCH; Tong, TSM; Fung, J; Hung, IFN; Yuen, MF | 2011 | 55 |
| Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation | Mukaide, M; Tanaka, Y; ShinI, T; Yuen, MF; Kurbanov, F; Yokosuka, O; Sata, M; Karino, Y; Yamada, G; Sakaguchi, K; Orito, E; Inoue, M; Baqai, S; Lai, CL; Mizokami, M | 2010 | 169 |
| Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B | Yuen, MF; Tanaka, Y; Fong, DYT; Fung, J; Wong, DKH; Yuen, JCH; But, DYK; Chan, AOO; Wong, BCY; Mizokami, M; Lai, CL | 2009 | 446 |
| The duration of lamivudine therapy for chronic hepatitis b: Cessation vs. continuation of treatment after HBeAg seroconversion | Fung, J; Lai, CL; Tanaka, Y; Mizokami, M; Yuen, J; Wong, DKH; Yuen, MF | 2009 | 58 |
| Three-year assessment of entecavir resistance in chronic hepatitis B patients and the mechanism of viral breakthrough by the resistance substitutions | Tanaka, Y; Mukaide, M; Yuen, RMF; Shin, IT; Orito, E; Kurbanov, F; Fukai, K; Yokosuka, O; Sata, M; Ide, T; Karino, Y; Yamada, G; Sakaguchi, K; Inoue, M; Gish, RG; Lai, CL; Mizokami, M | 2008 | 184 |
| Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B | Yuen, RMF; Tanaka, Y; Fong, DYT; Fung, JYY; Wong, DKH; Yuen, JCH; But, D; Chan, AOO; Wong, BCY; Mizokami, M; Lai, CL | 2008 | 138 |
| Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels | Yuen, MF; Tanaka, Y; Shinkai, N; Poon, RT; But, DYK; Fong, DYT; Fung, J; Wong, DKH; Yuen, JCH; Mizokami, M; Lai, CL | 2008 | 438 |
| Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population | Fung, J; Lai, CL; Yuen, JCH; Wong, DKH; Tanaka, Y; Mizokami, M; Yuen, MF | 2007 | 102 |
| Profiles of HBV DNA, ALT and HBeAG status after stopping lamivudine in patients with HBeAg seroconversion | Fung, JYY; Lai, CL; Tanaka, Y; Mizokami, M; Yuen, JCH; Wong, DKH; Yuen, RMF | 2007 | 71 |
| Role of HBV genotypes, core promoter/precore mutations and HBV DNA levels on hepatocarcinogenesis | Yuen, RMF; Tanaka, Y; Shinkai, N; Poon, RTP; Fung, JYY; Wong, DKH; Yuen, JCH; Mizokami, M; Lai, CL | 2007 | 142 |
| Profiles of HBV DNA, ALT, and HBeAg status after stopping lamivudine in patients with HBeAg seroconversion | Fung, JYY; Lai, CL; Tanaka, Y; Mizokami, M; Yuen, JCH; Wong, DKH; Yuen, RMF | 2007 | 102 |
| Role of HBV genotypes, core promoter/precore mutations and HBV DNA levels on hepatocarcinogenesis | Yuen, RMF; Tanaka, Y; Shinkai, N; Poon, RTP; Fung, JYY; Wong, DKH; Yuen, JCH; Mizokami, M; Lai, CL | 2007 | 114 |
| Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection | Wong, DKH; Tanaka, Y; Lai, CL; Mizokami, M; Fung, J; Yuen, MF | 2007 | 66 |
| Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma | Tanaka, Y; Mukaide, M; Orito, E; Yuen, MF; Ito, K; Kurbanov, F; Sugauchi, F; Asahina, Y; Izumi, N; Kato, M; Lai, CL; Ueda, R; Mizokami, M | 2006 | 106 |
|
